Clinical Trial Update: Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating venetoclax plus quizartinib in FLT3-mutated acute myeloid leukemia was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Flt3-itd Mutation

Drugs mentioned

• Quizartinib (Quizartinib)
• Venclyxto (Venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-09-19